Who are Botox 200 UNT Injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): OnabotulinumtoxinA Injectable Product, OnabotulinumtoxinA (ONA), MYOBLOC, OnabotulinumtoxinA 100 UNT [Botox], Botox infiltration, incabotulinumtoxinA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/botox-200-unt-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Botox 200 UNT Injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Botox 200 UNT Injection (Botox 200 UNT Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Botulinum toxin. Area: Neurology, Dermatology, Aesthetics.

phase 3 Botulinum toxin SNARE complex (synaptobrevin/VAMP) Neurology, Dermatology, Aesthetics Small molecule Live · refreshed every 30 min

Target snapshot

Botox 200 UNT Injection (Botox 200 UNT Injection) — University of Gaziantep. Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Botox 200 UNT Injection TARGET	Botox 200 UNT Injection	University of Gaziantep	phase 3	Botulinum toxin	SNARE complex (synaptobrevin/VAMP)
OnabotulinumtoxinA Injectable Product	OnabotulinumtoxinA Injectable Product	University of Utah	marketed	Botulinum toxin	SNAP-25 (synaptosomal-associated protein 25)
OnabotulinumtoxinA (ONA)	OnabotulinumtoxinA (ONA)	Hexsel Dermatology Clinic	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
MYOBLOC	MYOBLOC	Supernus Pharmaceuticals, Inc.	marketed	Botulinum toxin type B	VAMP/synaptobrevin (SNARE protein)
OnabotulinumtoxinA 100 UNT [Botox]	OnabotulinumtoxinA 100 UNT [Botox]	Women and Infants Hospital of Rhode Island	marketed	Neurotoxin; botulinum toxin type A	SNAP-25 (synaptosome-associated protein of 25 kDa)
Botox infiltration	Botox infiltration	University Rovira i Virgili	marketed	Neurotoxin; botulinum toxin type A	SNARE complex (synaptosome-associated protein); acetylcholine release machinery
incabotulinumtoxinA	incabotulinumtoxinA	Multiple Sclerosis Center of Northeastern New York	marketed	Botulinum toxin type A	SNARE complex (synaptobrevin/VAMP)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Botulinum toxin class)

Galderma R&D · 2 drugs in this class
Hexsel Dermatology Clinic · 2 drugs in this class
Seoul National University Hospital · 2 drugs in this class
University of Utah · 2 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 2 drugs in this class
EuBiologics Co.,Ltd · 1 drug in this class
Allergan · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Beth Israel Deaconess Medical Center · 1 drug in this class
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Botox 200 UNT Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/botox-200-unt-injection. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing